Abstract
Bankole Johnson, D.Sc., M.D., is the chairman of Adial Pharmaceuticals, which is developing a medication—AD04, a very low‐dose formulation of ondansetron—for the treatment of alcohol use disorders (AUDs). Johnson has long studied medications – ondansetron in particular ‐‐ to treat AUDs (see ADAW, Oct. 15, 2007, Feb. 11, 2008, June 16, 2008, Nov. 3, 2008, June 7, 2010, August 16, 2010, Jan. 31, 2011, Feb. 24, 2014), and most recently has been named the 2019 recipient of the American Society of Addiction Medicine's (ASAM's) R. Brinkley Smithers Distinguished Scientist Award, which will be presented, along with the accompanying lecture, at ASAM's annual conference in Orlando next month.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
